<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89165">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02061852</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A00079-38</org_study_id>
    <nct_id>NCT02061852</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety of the Medical Device Simeox®</brief_title>
  <acronym>SIMETOL</acronym>
  <official_title>Prospective Trial for the Evaluation of Safety, Tolerability and Efficacy of the Medical Device Simeox ® Compared to Traditional Respiratory Physiotherapy Techniques for Airway Secretion Clearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Physio-Assist</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mediaclin</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Physio-Assist</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the medical device &quot;simeox&quot; is safe in the
      treatment of respiratory diseases, in comparison with traditional physiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of the simeox®</measure>
    <time_frame>Day 8</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events related or not to the simeox®</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Broncho-degenerative Disease</condition>
  <condition>Chronic Obstructive Airway Disease</condition>
  <condition>Cystic Fibrosis</condition>
  <condition>Idiopathic Bronchiectasis</condition>
  <condition>Ciliary Dyskinesia</condition>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Physiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional techniques</description>
  </arm_group>
  <arm_group>
    <arm_group_label>simeox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medical device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Simeox</intervention_name>
    <arm_group_label>Physiotherapy</arm_group_label>
    <arm_group_label>simeox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physiotherapy</intervention_name>
    <arm_group_label>Physiotherapy</arm_group_label>
    <arm_group_label>simeox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18, male or female.

          -  Patient affected by broncho-degenerative disease, chronic obstructive airway disease,
             cystic fibrosis, idiopathic bronchiectasis, ciliary dyskinesia and/or chronic
             bronchitis.

          -  Hospitalization for a minimum of five days or a maximum of 8 days.

          -  Bronchial clearance is usually productive.

          -  FVC and / or FEV &lt;85% predicted, with stable lung function.

          -  Agreement to participate to the study and signature of the informed consent form

          -  Social security coverage.

        Exclusion Criteria:

          -  Patient infected with bacteria resistant to antibiotics.

          -  Bronchial clearance is not usually productive.

          -  Patient with contra-indication for physiotherapy bronchial clearance.

          -  Patient who received a lung transplant.

          -  Care requires more than 2 sessions of chest physiotherapy daily.

          -  Duration of mechanical ventilation &gt; 8h/day.

          -  Patient with an episode of hemoptysis during the month before inclusion.

          -  Patient with an episode of pneumothorax during the last month.

          -  Pregnant or lactating women.

          -  Patient with a disability and/or unwillingness to follow protocol requirements.

          -  Patient participating in another clinical study or having tested an experimental drug
             within 30 days prior to his inclusion in the study.

          -  Patient ( s) with another condition which, according to the investigator , may
             interfere with the result or conduct of the trial and thus justify their non-
             inclusion in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine Reynaud-Gaubert, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915 Cedex 20</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine REYNAUD-GAUBERT, Prof.</last_name>
      <phone>+ 334 91 96 61 45</phone>
      <email>martine.reynaud@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Martine REYNAUD-GAUBERT, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
